San Francisco, CA – Midjourney, the artificial intelligence company primarily recognized for its advanced image generation capabilities, has announced a significant expansion into the healthcare sector with the introduction of "Midjourney Medical." This new division plans to launch a full-body ultrasound scanner, dubbed "Ultrasonic CT," and integrate it into a flagship health spa in downtown San Francisco by late 2027. The initiative aims to revolutionize preventative healthcare by offering rapid, non-invasive body scans within a wellness-focused environment.
The new Midjourney Spa, set to open near Union Square, will feature amenities such as hot tubs, saunas, and cold plunges, alongside its proprietary medical imaging technology. According to Sheel Mohnot, who shared details on social media, the Ultrasonic CT scanner can perform a full-body scan in just 60 seconds, utilizing sound and water without radiation or powerful magnetic fields. Midjourney's goal is to deploy 50,000 of these scanners globally over the next six years, targeting an ambitious one billion full-body scans monthly.
Midjourney CEO David Holz described the technology as "the first new whole-body medical imaging modality in 50 years," asserting it to be as powerful as an MRI but with the casualness of a spa visit. The company intends for the scans to be a "side-effect" of a relaxing spa experience, providing users with a comprehensive library of health data. This strategic pivot marks Midjourney's first foray into hardware and healthcare, building on its expertise in complex image reconstruction algorithms.
The company, which is bootstrapped and operates without traditional VC funding, has licensed Butterfly Network's ultrasound-on-chip technology for its scanners. While Midjourney envisions the system as a tool for preventative health and body monitoring, medical experts have expressed caution, noting that the technology has not yet received FDA approval for diagnostic purposes. The company plans to initially offer non-diagnostic "body composition maps" and will pursue regulatory clearances for broader medical applications.
